In order to be eligible for enrollment in this study, subjects will need to be aged 18 years and above (18-65 for Czech Republic) and be clinically diagnosed with with mild or moderate ulcerative colitis and on a fixed dose of 5-ASA treatment (0 mg dose of 5-ASA is acceptable) and have been on a stable dose for at least 2 weeks prior to screening.